Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06457906). This is a study registration, not published results. Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 340 participants (ESTIMATED). Conditions: Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy, Whole Brain Radiotherpay, Hippocampal-avoidance. Interventions: COMBINATION_PRODUCT: Experimental group (SRS/SRT/Hypo-RT); RADIATION: Controled group (HA-WBRT). Primary outcome measures: Cognitive function scores , At 6 months after radiotherapy.; Meadian OS time , Measured at months 3, 6, 9, 12, 15,18, 21, 24, 30, 36,42,48,60 months after radiotherapy. Brief summary: This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain.